Researcher.Life Logo

Cardio-Oncology : Impact Factor & More

eISSN: 2057-3804pISSN: 2057-3804
JournalOpen Access

Key Metrics

CiteScore
2.3
SNIP
0.88
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Cardio-Oncology

Cardio-Oncology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2090 | USD 2490 | GBP 1690
Publication Time7
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2015
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
PlagiarismVisit website
Publication Time 7
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in Cardio-Oncology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Cardio-Oncology

SWATH-MS for discovery of early biomarkers of drug-induced cardiotoxicity using an animal doxorubicin model.
  • 13 May 2026
  • Cardio-oncology (London, England)
Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.
  • 9 May 2026
  • Cardio-oncology (London, England)
Role of ivabradine for anthracycline-induced cardiotoxicity: a meta-analysis.
  • 9 May 2026
  • Cardio-oncology (London, England)
Clinical utility of the HFA-ICOS risk tool in real-world HER2-positive breast cancer patients receiving therapy.
  • 8 May 2026
  • Cardio-oncology (London, England)
Echocardiographically occult nonbacterial thrombotic endocarditis with tumor cell-containing valvular vegetations in metastatic breast cancer.
  • 7 May 2026
  • Cardio-oncology (London, England)
Endoscopic ultrasound-guided transoesophageal pericardiocentesis: a case report on a therapeutic solution for pericardial tamponade with malignant posterior pericardial effusion.
  • 30 Apr 2026
  • Cardio-oncology (London, England)
SWATH-MS for discovery of early biomarkers of drug-induced cardiotoxicity using an animal doxorubicin model.
  • 13 May 2026
  • Cardio-oncology (London, England)
Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.
  • 9 May 2026
  • Cardio-oncology (London, England)
Role of ivabradine for anthracycline-induced cardiotoxicity: a meta-analysis.
  • 9 May 2026
  • Cardio-oncology (London, England)
Clinical utility of the HFA-ICOS risk tool in real-world HER2-positive breast cancer patients receiving therapy.
  • 8 May 2026
  • Cardio-oncology (London, England)
Echocardiographically occult nonbacterial thrombotic endocarditis with tumor cell-containing valvular vegetations in metastatic breast cancer.
  • 7 May 2026
  • Cardio-oncology (London, England)
Endoscopic ultrasound-guided transoesophageal pericardiocentesis: a case report on a therapeutic solution for pericardial tamponade with malignant posterior pericardial effusion.
  • 30 Apr 2026
  • Cardio-oncology (London, England)

FAQs on Cardio-Oncology